CQ-16

• UNSPSC Description:

  CQ-16 is an orally active small molecule drug conjugate (SMDC) targeting prostate-specific membrane antigen (PSMA). CQ-16 exhibits highly selective antiproliferative activity between PSMA-positive and PSMA-negative prostate cells. In addition, CQ-16 also has PARP inhibitory activity (IC50=1 nM). (Pink: PSMA Ligand (HY-139840); Black: Linker (HY-W037980); Blue: PARP Inhibitor (HY-10162))[1]

• Target Antigen:

  PARP; PSMA

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Epigenetics;Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cq-16.html

• Smiles:

  O=C1NN=C(C2=CC=CC=C21)CC3=CC=C(C(C(N4CCN(CC4)C(C5(NC(CCC(NCCCC[C@H](NC(N[C@H](C(O)=O)CCC(O)=O)=O)C(O)=O)=O)=O)CC5)=O)=O)=C3)F

• Molecular Weight:

  850.85

• References & Citations:

  [1]Chen Q, et al. A Prostate-Specific Membrane Antigen-Targeting Small Molecule–Drug Conjugate Strategy to Overcome the Hematological Toxicity of Olaparib[J]. Journal of Medicinal Chemistry, 2024.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  3024354-59-1